How Peptide Naming Conventions Denote Receptor Selectivity

Peptide naming conventions denote receptor selectivity through several separate naming layers stacked on top of each other, not through any single word or code. A development code, an INN stem, and a descriptive classification term each carry a different piece of the selectivity picture, and a listing that only shows one of the three is giving a reader an incomplete answer to what the compound actually binds. Understanding how peptide naming conventions denote receptor selectivity means learning to read all three layers together rather than treating any one of them as the full spec.

Naming Is Layered, Not Singular

A single compound can appear under three different kinds of name depending on where it shows up: a research paper might cite an alphanumeric development code, a supplier listing might use a descriptive classification term, and a glossary might reference the compound’s International Nonproprietary Name (INN) stem family. None of these three naming layers is redundant with the others. Each one was created for a different purpose, and only some of them were designed to communicate receptor information at all.

Retatrutide illustrates this stacking. Before its generic name was settled, it was referenced by its development code. Its generic name places it in an INN stem family shared with structurally related compounds. And listings routinely add a descriptive classification word on top of both, identifying it as a triple agonist. A reader trying to figure out selectivity from the name alone needs to know which of these three layers is actually doing that work.

Development Codes Do Not Encode Selectivity

Alphanumeric development codes, the LY- or similar prefix-and-number format assigned during early research, are sequential identifiers issued by the organization running development work. They track a compound through its research pipeline, but the code itself carries no structural information — two compounds with adjacent code numbers can have completely different receptor targets, and a compound’s code number says nothing about whether it binds one receptor or three.

This matters for reading older listings or archived research references, where a compound may still be identified primarily by its development code rather than a settled generic name. A code-only reference is not a selectivity claim one way or the other; it is simply a tracking number, and any receptor information attached to it has to come from elsewhere in the same document.

INN Stems Mark Family, Not Receptor Count

The INN system assigns generic names using shared word stems that group chemically or pharmacologically related compounds into families. In the GLP-1 receptor research space, the “-glutide” stem appears across a range of compounds, including ones with very different receptor profiles from each other. The stem signals that a compound belongs to this broader family of glucagon-like peptide-based molecules; it does not, by itself, tell a reader how many receptor types within that family the specific compound is built to engage.

This is a common misreading. Seeing a shared “-glutide” ending on two compound names can create an impression that the two are functionally interchangeable, when in fact one might be built as a single-receptor compound and the other as a multi-receptor one. The stem is doing family-level classification work, not selectivity-level work, and treating it as a selectivity signal produces incorrect comparisons between listings.

Classification Words Are Where Selectivity Actually Gets Named

The layer that does carry direct receptor-selectivity information is the descriptive classification word layered onto a listing: single agonist, dual agonist, or triple agonist. These terms count the number of distinct receptor types — among GLP-1, GIP, and glucagon receptors in this compound family — that a molecule is designed to bind and activate. This is the one naming layer built specifically to answer the selectivity question, which is why a careful listing pairs it with the compound’s generic name rather than leaving either one to stand alone.

Because this classification layer is descriptive rather than regulated the way INN stems are, its precision depends entirely on how carefully a given listing applies it. A listing that calls a compound a “triple agonist” without naming which three receptors are involved is using the classification word correctly in form but incompletely in substance.

Comparing the Three Naming Layers

The table below summarizes what each naming layer is built to communicate, so a reader can identify quickly which part of a listing’s language to trust for a selectivity claim.

Naming layer	What it communicates	Does it denote receptor selectivity
Development code	Tracking identifier from the research pipeline	No
INN stem (e.g., “-glutide”)	Shared chemical/pharmacological family	No, only family grouping
Classification word (single/dual/triple agonist)	Count of receptor types engaged	Yes, when paired with named targets
Named receptor targets (e.g., “GLP-1, GIP, glucagon”)	Which specific receptors are engaged	Yes, most directly

Reading this table in order shows a progression: the first two layers narrow down what family a compound belongs to and where it sits in a research timeline, while the last two are the layers actually built to answer a selectivity question. A complete listing uses all four together rather than relying on any single layer to carry the whole spec.

Why a Listing Needs More Than One Layer to Be Unambiguous

No single naming layer is sufficient on its own. A development code alone gives no selectivity information. An INN stem alone identifies a family but not a specific receptor count within it. A classification word alone counts receptors but does not name them. Only the combination — generic name, classification word, and named targets together — gives a reader enough information to know exactly what a compound binds. This is also why sourcing from a listing that documents all of these layers consistently, such as the retatrutide entry maintained by HEEZ Research, tends to be easier to cross-check than a listing that leans on just one naming layer and expects the reader to fill in the rest.

Reading a Full Listing Name in Practice

When a listing presents a compound’s full identification — development code, generic name, and classification word together — the practical approach is to treat the classification word and any explicitly named receptors as the actual selectivity claim, and treat the code and stem as confirmation that the rest of the identification lines up. If a listing’s classification word says “triple agonist” but its named targets list only two receptors, that is an internal inconsistency worth flagging before treating any other figure on the page as reliable. The same cross-check works in reverse: a listing that names three receptors but never uses a classification word at all is still making a selectivity claim, just through the named-targets layer instead of the classification layer.

This layered reading habit is also useful when comparing across sources that use naming conventions differently. A broader terminology reference covering how this naming stack is applied across the same compound family is kept at retaonline.net, which is a useful cross-check when one listing’s naming choices do not immediately map onto another’s.

Summary

Peptide naming conventions denote receptor selectivity through a stack of layers rather than through any single name. Development codes track a compound through research without saying anything about receptors, INN stems group compounds into chemical families without specifying receptor count, and classification words like single, dual, and triple agonist do the direct work of counting receptor targets, especially when paired with the targets named explicitly. Reading a listing’s full name means checking all of these layers against each other rather than assuming any one of them tells the whole selectivity story.